Employers Shifted GLP-1 Coverage to HRA Models
Large employers are moving toward fixed-contribution plans to help manage rising GLP-1 medication costs for employees.
Updated on Oct. 13, 2026 in Weight Loss
Live Poll
Should employers be allowed to cap coverage for expensive weight management medications?
Alight has launched a health reimbursement account (HRA) product designed to manage GLP-1 weight loss medication coverage as companies scale back open-ended benefit structures. This shift comes as the proportion of large employers offering GLP-1 coverage dropped from 72% in 2025 to 60% in 2026.
Why it matters
Employers are increasingly adopting fixed-funding models to control the high costs of branded GLP-1 injectables, which can range from $1,000 to $1,500 monthly, while still providing some level of employee access to these therapies.
A survey of large employers conducted in June 2026 shows a 12 percentage point decrease in GLP-1 coverage over one year, with 14% of firms planning to discontinue coverage by 2027. Researchers note that GLP-1 prescriptions now account for 42% of all reviews for Alight Navigation members.
The players
Alight
A Deerfield, Illinois-based human resources and benefits consulting firm that manages health navigation services for 30 million people.
WEX
A financial technology company that provides benefits management tools, including healthcare-specific payment products.
The details
The new HRA model works by removing GLP-1 medications from a company's main drug plan and moving them into an excepted benefit account. Employers set specific eligibility criteria and fund the account with a fixed monthly or annual contribution, such as the 2026 cap of $2,200. This structure allows organizations to cap their financial exposure to expensive weight management injectables while enabling employees to use those designated funds for their out-of-pocket costs.
Timeline
2024: GLP-1 drugs represented 32% of prescriptions reviewed for Alight members.
2025: 72% of large employers provided coverage for GLP-1 agonists.
March 2026: WEX introduced a comparable HRA product for GLP-1 medications.
June 2 to June 12, 2026: The International Foundation of Employee Benefit Plans conducted its survey.
October 13, 2026: Alight launched its new GLP-1 HRA product.
Health Landscape
The introduction of HRA carve-outs represents a strategic pivot in the corporate benefits landscape as organizations move away from traditional open-ended drug plans. This trend follows the broader shift toward restrictive coverage policies documented by the International Foundation of Employee Benefit Plans 2026 coverage survey.
If your employer transitions to an HRA model, review your benefits documentation to understand your specific contribution limit and whether it covers your medication costs throughout the year. It is worth discussing with your doctor how any changes in your coverage might influence your long-term treatment plan.
The takeaway
Employers are moving toward fixed-benefit models to manage the rising expense of obesity medications. If you have concerns about your prescription coverage, contact your HR department to verify your specific account limits and eligibility criteria for the upcoming plan year.
Further reading
For a broader look at how companies manage obesity care, explore our Weight Loss section.
Live Poll
Should employers be allowed to cap coverage for expensive weight management medications?
